Dossiers

The judgement layer is the product. Agents run screening triage, gather evidence, review alerts and monitor profiles, which is the analyst work that consumes a compliance function's hours, and the company's argument is explicitly that static rules catch a fraction of laundering moving through layered networks of shell companies and intermediaries. Remove the models and what remains is list matching and a case queue, which is the legacy system it is selling against. The South Asia data coverage is a real and separate asset, and it feeds the models rather than substituting for them.

The oversight position is stated in the product description rather than left to inference. Agents are framed as working alongside the compliance team rather than replacing it, and every agent action is described as logged, explainable and auditable, which is the right shape for a function where an examiner will ask who decided and on what basis. It falls short of an A because nothing names which decisions the agents close on their own, which escalate, or what happens when an agent clears a hit that should have been escalated.

The measurable claims a screening vendor should publish are absent: no match precision, no false positive rate, no recall on known cases, no tuning methodology and no validation summary a bank could hand to its own model risk function. The auditability commitment helps a reviewer reconstruct a single decision after the fact, which is worth having, and it says nothing about how often the system is right.

No institution is named, no alert volume, false positive reduction or investigation time figure is published, and no independent evaluation exists. Press coverage at launch and an early funding round establish that the company is real and funded, which is not the same as evidence the product performs. This is the expected position for a young company and is recorded rather than penalised further.

The data provenance question is unusually interesting here and unusually unanswered. The founding team came out of fact checking and data journalism with ties to international investigative reporting networks, which is a real capability for building risk data where official records are thin, and it also means adverse information may originate in journalism rather than in official listings. Nothing published describes how a source is verified, how an allegation is distinguished from a finding, how a profile is corrected, or whether client screening activity informs the shared data set.

Screening builds profiles of named individuals from public and third party sources, which is the most privacy sensitive activity in this lane, and nothing published states retention periods, subject rights handling, the lawful basis for compiling adverse information, or how a person is treated once a profile exists. Several markets in the region now have data protection statutes in force, and no source located addresses them.

No certification, attestation or trust page was located. A compliance platform holds identity documents, screening results and investigation notes, which is among the most sensitive data a bank hands to a supplier, so an attestation will be the first thing a procurement team asks for as the company moves upmarket.

No licence is required for a screening vendor and none is claimed. The regulatory framing is better than most at this stage, naming central bank and financial intelligence unit obligations and the international standard setter's grey listing as the pressure its buyers face, which shows the product was built against a real supervisory regime. What is missing is specificity: no notice, regulation or jurisdiction is cited by name, and no supervisory registration or assessment is claimed.

Name screening is where fairness problems in this lane actually live, and this product sits directly on top of the hardest version of it. Matching across scripts and transliteration systems produces uneven error rates, and names common in South Asia generate more variants and more false matches than the Latin script names most matching systems were tuned on, which is the same finding recorded elsewhere in this index.

Adverse media screening compounds it, since press coverage density varies by country, language and political context, so a person in a heavily reported market accumulates more hits than an equivalent person elsewhere. Nothing published addresses matching accuracy by script, language or region.

A screening hit can cost someone a bank account, and in the markets this vendor targets a rejected applicant may have no realistic alternative provider. Nothing published describes how a person contests a match, how a wrong profile is corrected at source, or how long a cleared false positive keeps resurfacing. The institution carries the regulatory duty either way, and the person carries the consequence with no route to the vendor.

Nothing names the model components, the providers behind them, the watchlist and sanctions sources the screening runs against, or the infrastructure it runs on. Sanctions and politically exposed person data is normally licensed from a small number of global suppliers, so which of those sit underneath, and what the regional coverage is built from instead, is exactly what a buyer choosing this over an incumbent would need to know.

Nothing published names a core banking system, onboarding platform, case management tool or data provider it connects to. The platform is described as bringing onboarding, screening and monitoring together in one place, which implies it expects to be the system of record for compliance rather than a layer inside someone else's, and for a bank with an existing core that is the integration question to ask.

No hosting model, region or residency commitment is published. This matters more than average for the intended buyer, since several regulators in the region require customer data to remain onshore and a Singapore hosted platform serving South Asian institutions runs straight into that question.

No pricing, tier structure or billing basis is published. For a buyer in an emerging market, where the alternative is often a global screening vendor priced for a different economy, the cost position would be a genuine differentiator and it is not stated anywhere.

Coverage spans banks, fintechs and other regulated firms across the customer lifecycle from onboarding through screening to ongoing monitoring, with a deliberate regional concentration in South Asia and adjacent emerging markets. That concentration is the reason to take the company seriously rather than a limitation, since screening coverage in those markets is the acknowledged weak point of the global vendors and the reason institutions there carry higher false positive burdens. Held at B because no market share, deployment count or institution size range is published.